Bicara Therapeutics (BCAX) Competitors $18.38 -0.94 (-4.87%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends BCAX vs. OGN, IBRX, IMVT, RYTM, APLS, MLTX, AGIO, DYN, VRNA, and PTCTShould you be buying Bicara Therapeutics stock or one of its competitors? The main competitors of Bicara Therapeutics include Organon & Co. (OGN), ImmunityBio (IBRX), Immunovant (IMVT), Rhythm Pharmaceuticals (RYTM), Apellis Pharmaceuticals (APLS), MoonLake Immunotherapeutics (MLTX), Agios Pharmaceuticals (AGIO), Dyne Therapeutics (DYN), Verona Pharma (VRNA), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry. Bicara Therapeutics vs. Organon & Co. ImmunityBio Immunovant Rhythm Pharmaceuticals Apellis Pharmaceuticals MoonLake Immunotherapeutics Agios Pharmaceuticals Dyne Therapeutics Verona Pharma PTC Therapeutics Bicara Therapeutics (NASDAQ:BCAX) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Is BCAX or OGN more profitable? Organon & Co. has a net margin of 20.30% compared to Bicara Therapeutics' net margin of 0.00%. Organon & Co.'s return on equity of 644.70% beat Bicara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Organon & Co. 20.30%644.70%8.12% Do insiders and institutionals have more ownership in BCAX or OGN? 77.4% of Organon & Co. shares are held by institutional investors. 1.4% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media refer more to BCAX or OGN? In the previous week, Bicara Therapeutics had 7 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Bicara Therapeutics and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.92 beat Bicara Therapeutics' score of -0.06 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Organon & Co. 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer BCAX or OGN? Organon & Co. received 11 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 34.00% of users gave Organon & Co. an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes6100.00% Underperform VotesNo VotesOrganon & Co.Outperform Votes1734.00% Underperform Votes3366.00% Do analysts rate BCAX or OGN? Bicara Therapeutics presently has a consensus target price of $43.33, suggesting a potential upside of 135.76%. Organon & Co. has a consensus target price of $21.33, suggesting a potential upside of 44.88%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Bicara Therapeutics is more favorable than Organon & Co..Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Organon & Co. 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Which has preferable valuation and earnings, BCAX or OGN? Organon & Co. has higher revenue and earnings than Bicara Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/AOrganon & Co.$6.26B0.61$1.02B$5.042.92 SummaryOrganon & Co. beats Bicara Therapeutics on 8 of the 13 factors compared between the two stocks. Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCAX vs. The Competition Export to ExcelMetricBicara TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.00B$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E RatioN/A5.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / BookN/A7.885.805.12Net IncomeN/A$153.61M$119.07M$225.99M7 Day Performance-17.39%-2.00%-1.83%-1.32%1 Month Performance-18.24%-7.47%-3.64%0.60%1 Year PerformanceN/A31.80%31.62%26.23% Bicara Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCAXBicara Therapeutics3.1692 of 5 stars$18.38-4.9%$43.33+135.8%N/A$1.00BN/A0.0032Analyst RevisionOGNOrganon & Co.4.7217 of 5 stars$14.73+0.9%$21.33+44.9%+31.6%$3.76B$6.26B2.9210,000IBRXImmunityBio0.735 of 5 stars$4.88-8.8%$4.75-2.6%+20.4%$3.73B$620,000.000.00590Positive NewsIMVTImmunovant1.5467 of 5 stars$26.17+3.8%$48.10+83.8%-22.6%$3.70BN/A0.00120RYTMRhythm Pharmaceuticals2.8994 of 5 stars$59.36-1.0%$62.30+5.0%+78.0%$3.69B$77.43M0.00140Analyst ForecastAPLSApellis Pharmaceuticals4.5376 of 5 stars$27.49-5.2%$51.06+85.7%-44.5%$3.42B$396.59M-13.54702MLTXMoonLake Immunotherapeutics3.2689 of 5 stars$49.82+1.0%$79.00+58.6%+16.8%$3.15BN/A0.002AGIOAgios Pharmaceuticals3.3113 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390DYNDyne Therapeutics3.3831 of 5 stars$29.99+1.0%$51.40+71.4%+181.6%$3.05BN/A-8.42100Insider TradeAnalyst RevisionVRNAVerona Pharma2.5968 of 5 stars$38.85+2.0%$43.83+12.8%+163.7%$3.04B$460,000.000.0030Positive NewsPTCTPTC Therapeutics2.5538 of 5 stars$41.96+6.6%$42.00+0.1%+89.3%$3.04B$937.82M0.001,410Analyst Downgrade Related Companies and Tools Related Companies OGN Competitors IBRX Competitors IMVT Competitors RYTM Competitors APLS Competitors MLTX Competitors AGIO Competitors DYN Competitors VRNA Competitors PTCT Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCAX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BCAX Stock Alerts